Long-Term Survival in Metastatic Pancreatic Adenocarcinoma of Intestinal Type
Pancreatic cancer is often diagnosed in an advanced/metastatic stage, as it is a very aggressive type of cancer. The prognosis of pancreatic cancer is extremely unfavorable. The mean survival rate for patients with metastatic pancreatic adenocarcinoma is 3-6 months. Stage IV pancreatic cancer has a...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2024-08, Vol.13 (17), p.5034 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 17 |
| container_start_page | 5034 |
| container_title | Journal of clinical medicine |
| container_volume | 13 |
| creator | Rahnea-Nita, Gabriela Rebegea, Laura-Florentina Grigorean, Valentin Titus Coman, Ionuţ Simion Coman, Violeta Elena Pleşea, Iancu Emil Erchid, Anwar Florea, Costin George Liţescu, Mircea Rahnea-Nita, Roxana-Andreea |
| description | Pancreatic cancer is often diagnosed in an advanced/metastatic stage, as it is a very aggressive type of cancer. The prognosis of pancreatic cancer is extremely unfavorable. The mean survival rate for patients with metastatic pancreatic adenocarcinoma is 3-6 months. Stage IV pancreatic cancer has a five-year survival rate of 1.3% to 13%. This article presents recent data regarding the oncologic management of metastatic pancreatic cancer.
We present the case of a female patient who was 49 years old at the time of diagnosis, in June 2021. The patient was diagnosed with stage IV pancreatic neoplasm (due to liver metastases). The diagnosis was made by histopathological and immunohistochemical examination, which corroborated imaging investigations. The patient underwent four lines of chemotherapy between July 2021 and July 2024, undergoing partial response to the disease. The patient is a long-term survivor of metastatic pancreatic cancer (3 years in July 2024).
the peculiarity of this case is long-term survival (3 years and a month at the date when this article is being written) in a patient with pancreatic cancer and liver metastases.
histopathological type, good performance status, CEA, and CA tumor markers 19.9 within normal limits may be favorable prognostic factors for long-term survival in metastatic pancreatic carcinoma. |
| doi_str_mv | 10.3390/jcm13175034 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3104541989</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3104012091</sourcerecordid><originalsourceid>FETCH-LOGICAL-c205t-89d503e7fd1b65a95a683a412e7aad0dd0b2a16fb4758caca40dd239d44742a33</originalsourceid><addsrcrecordid>eNpdkN1LwzAUxYMobsw9-S4FXwSp5qtL8ziGH4MNBedzuU1S6WiTmbSD_fdGN2V4X-7h8ruHw0HokuA7xiS-X6uWMCIyzPgJGlIsRIpZzk6P9ACNQ1jjOHnOKRHnaMAkFZxyMUTLhbMf6cr4Nnnr_bbeQpPUNlmaDkIHXa2SV7DKmx851cY6BV7V1rWQuCqZ286Errbxa7XbmAt0VkETzPiwR-j98WE1e04XL0_z2XSRKoqzLs2ljoGNqDQpJxnIDCY5A06oEQAaa41LCmRSlVxkuQIFPN4ok5rzGBsYG6Gbve_Gu88-JijaOijTNGCN60PBCOYZJzKXEb3-h65d72PgPYUJxZJE6nZPKe9C8KYqNr5uwe8KgovvooujoiN9dfDsy9boP_a3VvYF4Ll3Vg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3104012091</pqid></control><display><type>article</type><title>Long-Term Survival in Metastatic Pancreatic Adenocarcinoma of Intestinal Type</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Rahnea-Nita, Gabriela ; Rebegea, Laura-Florentina ; Grigorean, Valentin Titus ; Coman, Ionuţ Simion ; Coman, Violeta Elena ; Pleşea, Iancu Emil ; Erchid, Anwar ; Florea, Costin George ; Liţescu, Mircea ; Rahnea-Nita, Roxana-Andreea</creator><creatorcontrib>Rahnea-Nita, Gabriela ; Rebegea, Laura-Florentina ; Grigorean, Valentin Titus ; Coman, Ionuţ Simion ; Coman, Violeta Elena ; Pleşea, Iancu Emil ; Erchid, Anwar ; Florea, Costin George ; Liţescu, Mircea ; Rahnea-Nita, Roxana-Andreea</creatorcontrib><description>Pancreatic cancer is often diagnosed in an advanced/metastatic stage, as it is a very aggressive type of cancer. The prognosis of pancreatic cancer is extremely unfavorable. The mean survival rate for patients with metastatic pancreatic adenocarcinoma is 3-6 months. Stage IV pancreatic cancer has a five-year survival rate of 1.3% to 13%. This article presents recent data regarding the oncologic management of metastatic pancreatic cancer.
We present the case of a female patient who was 49 years old at the time of diagnosis, in June 2021. The patient was diagnosed with stage IV pancreatic neoplasm (due to liver metastases). The diagnosis was made by histopathological and immunohistochemical examination, which corroborated imaging investigations. The patient underwent four lines of chemotherapy between July 2021 and July 2024, undergoing partial response to the disease. The patient is a long-term survivor of metastatic pancreatic cancer (3 years in July 2024).
the peculiarity of this case is long-term survival (3 years and a month at the date when this article is being written) in a patient with pancreatic cancer and liver metastases.
histopathological type, good performance status, CEA, and CA tumor markers 19.9 within normal limits may be favorable prognostic factors for long-term survival in metastatic pancreatic carcinoma.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm13175034</identifier><identifier>PMID: 39274247</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Abdomen ; Adjuvants ; Bile ducts ; Cancer therapies ; Case reports ; Chemotherapy ; Epidemiology ; Immunotherapy ; Literature reviews ; Medical prognosis ; Metastasis ; Mutation ; Pancreatic cancer ; Patients ; Small intestine ; Tumors</subject><ispartof>Journal of clinical medicine, 2024-08, Vol.13 (17), p.5034</ispartof><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c205t-89d503e7fd1b65a95a683a412e7aad0dd0b2a16fb4758caca40dd239d44742a33</cites><orcidid>0000-0001-6022-2236 ; 0000-0003-1664-0291 ; 0000-0002-0535-7100</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39274247$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rahnea-Nita, Gabriela</creatorcontrib><creatorcontrib>Rebegea, Laura-Florentina</creatorcontrib><creatorcontrib>Grigorean, Valentin Titus</creatorcontrib><creatorcontrib>Coman, Ionuţ Simion</creatorcontrib><creatorcontrib>Coman, Violeta Elena</creatorcontrib><creatorcontrib>Pleşea, Iancu Emil</creatorcontrib><creatorcontrib>Erchid, Anwar</creatorcontrib><creatorcontrib>Florea, Costin George</creatorcontrib><creatorcontrib>Liţescu, Mircea</creatorcontrib><creatorcontrib>Rahnea-Nita, Roxana-Andreea</creatorcontrib><title>Long-Term Survival in Metastatic Pancreatic Adenocarcinoma of Intestinal Type</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>Pancreatic cancer is often diagnosed in an advanced/metastatic stage, as it is a very aggressive type of cancer. The prognosis of pancreatic cancer is extremely unfavorable. The mean survival rate for patients with metastatic pancreatic adenocarcinoma is 3-6 months. Stage IV pancreatic cancer has a five-year survival rate of 1.3% to 13%. This article presents recent data regarding the oncologic management of metastatic pancreatic cancer.
We present the case of a female patient who was 49 years old at the time of diagnosis, in June 2021. The patient was diagnosed with stage IV pancreatic neoplasm (due to liver metastases). The diagnosis was made by histopathological and immunohistochemical examination, which corroborated imaging investigations. The patient underwent four lines of chemotherapy between July 2021 and July 2024, undergoing partial response to the disease. The patient is a long-term survivor of metastatic pancreatic cancer (3 years in July 2024).
the peculiarity of this case is long-term survival (3 years and a month at the date when this article is being written) in a patient with pancreatic cancer and liver metastases.
histopathological type, good performance status, CEA, and CA tumor markers 19.9 within normal limits may be favorable prognostic factors for long-term survival in metastatic pancreatic carcinoma.</description><subject>Abdomen</subject><subject>Adjuvants</subject><subject>Bile ducts</subject><subject>Cancer therapies</subject><subject>Case reports</subject><subject>Chemotherapy</subject><subject>Epidemiology</subject><subject>Immunotherapy</subject><subject>Literature reviews</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Mutation</subject><subject>Pancreatic cancer</subject><subject>Patients</subject><subject>Small intestine</subject><subject>Tumors</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkN1LwzAUxYMobsw9-S4FXwSp5qtL8ziGH4MNBedzuU1S6WiTmbSD_fdGN2V4X-7h8ruHw0HokuA7xiS-X6uWMCIyzPgJGlIsRIpZzk6P9ACNQ1jjOHnOKRHnaMAkFZxyMUTLhbMf6cr4Nnnr_bbeQpPUNlmaDkIHXa2SV7DKmx851cY6BV7V1rWQuCqZ286Errbxa7XbmAt0VkETzPiwR-j98WE1e04XL0_z2XSRKoqzLs2ljoGNqDQpJxnIDCY5A06oEQAaa41LCmRSlVxkuQIFPN4ok5rzGBsYG6Gbve_Gu88-JijaOijTNGCN60PBCOYZJzKXEb3-h65d72PgPYUJxZJE6nZPKe9C8KYqNr5uwe8KgovvooujoiN9dfDsy9boP_a3VvYF4Ll3Vg</recordid><startdate>20240825</startdate><enddate>20240825</enddate><creator>Rahnea-Nita, Gabriela</creator><creator>Rebegea, Laura-Florentina</creator><creator>Grigorean, Valentin Titus</creator><creator>Coman, Ionuţ Simion</creator><creator>Coman, Violeta Elena</creator><creator>Pleşea, Iancu Emil</creator><creator>Erchid, Anwar</creator><creator>Florea, Costin George</creator><creator>Liţescu, Mircea</creator><creator>Rahnea-Nita, Roxana-Andreea</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6022-2236</orcidid><orcidid>https://orcid.org/0000-0003-1664-0291</orcidid><orcidid>https://orcid.org/0000-0002-0535-7100</orcidid></search><sort><creationdate>20240825</creationdate><title>Long-Term Survival in Metastatic Pancreatic Adenocarcinoma of Intestinal Type</title><author>Rahnea-Nita, Gabriela ; Rebegea, Laura-Florentina ; Grigorean, Valentin Titus ; Coman, Ionuţ Simion ; Coman, Violeta Elena ; Pleşea, Iancu Emil ; Erchid, Anwar ; Florea, Costin George ; Liţescu, Mircea ; Rahnea-Nita, Roxana-Andreea</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c205t-89d503e7fd1b65a95a683a412e7aad0dd0b2a16fb4758caca40dd239d44742a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Abdomen</topic><topic>Adjuvants</topic><topic>Bile ducts</topic><topic>Cancer therapies</topic><topic>Case reports</topic><topic>Chemotherapy</topic><topic>Epidemiology</topic><topic>Immunotherapy</topic><topic>Literature reviews</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Mutation</topic><topic>Pancreatic cancer</topic><topic>Patients</topic><topic>Small intestine</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rahnea-Nita, Gabriela</creatorcontrib><creatorcontrib>Rebegea, Laura-Florentina</creatorcontrib><creatorcontrib>Grigorean, Valentin Titus</creatorcontrib><creatorcontrib>Coman, Ionuţ Simion</creatorcontrib><creatorcontrib>Coman, Violeta Elena</creatorcontrib><creatorcontrib>Pleşea, Iancu Emil</creatorcontrib><creatorcontrib>Erchid, Anwar</creatorcontrib><creatorcontrib>Florea, Costin George</creatorcontrib><creatorcontrib>Liţescu, Mircea</creatorcontrib><creatorcontrib>Rahnea-Nita, Roxana-Andreea</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rahnea-Nita, Gabriela</au><au>Rebegea, Laura-Florentina</au><au>Grigorean, Valentin Titus</au><au>Coman, Ionuţ Simion</au><au>Coman, Violeta Elena</au><au>Pleşea, Iancu Emil</au><au>Erchid, Anwar</au><au>Florea, Costin George</au><au>Liţescu, Mircea</au><au>Rahnea-Nita, Roxana-Andreea</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-Term Survival in Metastatic Pancreatic Adenocarcinoma of Intestinal Type</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2024-08-25</date><risdate>2024</risdate><volume>13</volume><issue>17</issue><spage>5034</spage><pages>5034-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Pancreatic cancer is often diagnosed in an advanced/metastatic stage, as it is a very aggressive type of cancer. The prognosis of pancreatic cancer is extremely unfavorable. The mean survival rate for patients with metastatic pancreatic adenocarcinoma is 3-6 months. Stage IV pancreatic cancer has a five-year survival rate of 1.3% to 13%. This article presents recent data regarding the oncologic management of metastatic pancreatic cancer.
We present the case of a female patient who was 49 years old at the time of diagnosis, in June 2021. The patient was diagnosed with stage IV pancreatic neoplasm (due to liver metastases). The diagnosis was made by histopathological and immunohistochemical examination, which corroborated imaging investigations. The patient underwent four lines of chemotherapy between July 2021 and July 2024, undergoing partial response to the disease. The patient is a long-term survivor of metastatic pancreatic cancer (3 years in July 2024).
the peculiarity of this case is long-term survival (3 years and a month at the date when this article is being written) in a patient with pancreatic cancer and liver metastases.
histopathological type, good performance status, CEA, and CA tumor markers 19.9 within normal limits may be favorable prognostic factors for long-term survival in metastatic pancreatic carcinoma.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39274247</pmid><doi>10.3390/jcm13175034</doi><orcidid>https://orcid.org/0000-0001-6022-2236</orcidid><orcidid>https://orcid.org/0000-0003-1664-0291</orcidid><orcidid>https://orcid.org/0000-0002-0535-7100</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2024-08, Vol.13 (17), p.5034 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3104541989 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Abdomen Adjuvants Bile ducts Cancer therapies Case reports Chemotherapy Epidemiology Immunotherapy Literature reviews Medical prognosis Metastasis Mutation Pancreatic cancer Patients Small intestine Tumors |
| title | Long-Term Survival in Metastatic Pancreatic Adenocarcinoma of Intestinal Type |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T21%3A45%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-Term%20Survival%20in%20Metastatic%20Pancreatic%20Adenocarcinoma%20of%20Intestinal%20Type&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Rahnea-Nita,%20Gabriela&rft.date=2024-08-25&rft.volume=13&rft.issue=17&rft.spage=5034&rft.pages=5034-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm13175034&rft_dat=%3Cproquest_cross%3E3104012091%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3104012091&rft_id=info:pmid/39274247&rfr_iscdi=true |